← Back to ResearchSenolytic mechanism — macrophage eliminating senescent zombie cell with SASP halo

Senolytics Research Guide: Dasatinib & Quercetin

⚠️ Research Compounds — Not for Human Administration
Dasatinib and quercetin used as senolytics are research compounds. Dasatinib is an approved oncology drug with a distinct clinical indication (CML/ALL); its use in the senolytic context is investigational. All information is for scientific and educational purposes only. UNIK LAB does not provide medical advice.

Cellular senescence has moved from a niche concept in cell biology to one of the most actively funded areas in aging research. The reason is simple: in 2011, Baker et al. (PMID 22048312, Nature) published a landmark paper showing that selectively clearing p16Ink4a-positive senescent cells from a progeroid mouse model extended healthy lifespan and delayed multiple age-related pathologies.

What followed was a decade of work identifying compounds that selectively kill senescent cells — senolytics — and the first human clinical trials testing whether this strategy translates.

1. What Is Cellular Senescence?

Cellular senescence is a state of stable, irreversible cell cycle arrest — a condition where a cell has permanently stopped dividing but has not undergone apoptosis. Senescent cells remain metabolically active and can persist in tissues for years.

Senescence is triggered by:

  • Replicative senescence: telomere shortening after repeated cell division (the Hayflick limit)
  • Oncogene-induced senescence (OIS): activation of oncogenes that trigger a protective anti-proliferative response
  • Stress-induced premature senescence (SIPS): DNA damage, oxidative stress, radiation, chemotherapy
  • Paracrine/bystander senescence: SASP factors from existing senescent cells inducing senescence in neighbours

2. The SASP: Senescence-Associated Secretory Phenotype

Rather than simply stopping division, senescent cells secrete a complex mixture of inflammatory cytokines, chemokines, proteases, and growth factors that actively alter the surrounding tissue environment.

Key SASP components: IL-6, IL-8 (CXCL8), TNF-α, MMPs (matrix metalloproteinases), VEGF, TGF-β. The SASP creates a "senescence inflammatory loop" — SASP factors induce senescence in neighbouring cells, creating an expanding zone of dysfunction.

3. What Are Senolytics?

Senolytics are compounds that selectively induce apoptosis in senescent cells while leaving normal cells relatively unaffected. Zhu et al. (2015, PMID 25754370, Aging Cell) first identified the class by performing bioinformatic analysis of pro-survival gene expression patterns in senescent cells — mapping their "Achilles' heel" — and computationally identifying compounds that could target these survival pathways. Dasatinib and quercetin emerged from this analysis.

Senescent cells engage a pro-survival "SCAPs" network (Senescent Cell Anti-Apoptotic Pathways) including BCL-2/BCL-xL/BCL-W, PI3K/AKT, and p21/CDKN1A. Senolytics target these pro-survival mechanisms.

4. Dasatinib as a Senolytic: Mechanism

Dasatinib is a tyrosine kinase inhibitor approved for CML and ALL. As a senolytic, its most relevant target is the Src kinase family and the ephrin (EPHB4) receptor pathway. Dasatinib shows strong senolytic activity in adipocyte progenitors and endothelial cells — with less effect in senescent fibroblasts.

5. Quercetin as a Senolytic: Mechanism

Quercetin is a naturally occurring flavonoid. As a senolytic, it inhibits PI3K (reducing PI3K/AKT survival signalling), Bcl-2/Bcl-xL (partially), and Serpine 1 (PAI-1). Quercetin shows senolytic activity in fibroblasts and endothelial cells — complementary to dasatinib's target spectrum. Quercetin alone is a weaker senolytic; the D+Q combination produces synergistic effects.

6. First Human Trial Data: Justice et al. 2019 (IPF)

Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Kirkland JL et al. (EBioMedicine, 2019, PMID 30616998) — the first-ever human senolytic trial.

  • Design: Open-label, pilot study, 14 patients with idiopathic pulmonary fibrosis (IPF)
  • Intervention: 3 intermittent doses of dasatinib (100 mg) + quercetin (1,250 mg) over 3 consecutive days
  • Key findings: Significant reductions in circulating senescent cells (p16Ink4a, p21CIP1), decreased SASP factors (IL-6, TNF-α, MMPs), improvements in physical function metrics (6-minute walk distance, gait speed, chair-standing test)
  • Limitations: 14 patients, open-label (no placebo control), single arm

7. Second Human Trial: Hickson et al. 2019 (Diabetic Kidney Disease)

Hickson LJ et al. (EBioMedicine, 2019, PMID 31542391) — D+Q in patients with type 2 diabetes and stage 3a/3b chronic kidney disease.

  • Reductions in adipose tissue senescent cell burden (p16Ink4a, p21CIP1 expressing cells in fat tissue biopsies)
  • Reductions in circulating SASP factors (leptin, IGF-1)
  • Improvement in physical function tests
  • Confirmed that Justice et al. findings were not disease-specific to IPF

8. Other Senolytics in Research: Navitoclax, Fisetin, ABT-263

  • Navitoclax (ABT-263): BCL-2/BCL-xL/BCL-W inhibitor. Strong senolytic activity in animal models. Limitation: dose-dependent thrombocytopenia from BCL-xL inhibition in platelets.
  • Fisetin: Naturally occurring flavonoid. Yousefzadeh MJ, Zhu Y et al. (2018, PMID 30279143, EBioMedicine) demonstrated fisetin extends health and lifespan in mouse models, clearing senescent cells and reducing SASP. Better-tolerated but weaker senolytic than D+Q.
  • UBX0101: MDM2 inhibitor. Phase 2 trial for knee osteoarthritis failed (2020) — demonstrating that preclinical-to-clinical translation is not guaranteed.

9. Comparative Overview: Senolytics in Research

CompoundClassPrimary TargetCell Types TargetedHuman Trial StatusKey Limitation
DasatinibTyrosine kinase inhibitorSrc/EPHB4 kinaseFat progenitors, endothelial cellsPhase 1/2 (IPF, DKD, others)Approved drug repurposed; off-label in aging
QuercetinFlavonoidPI3K / BCL-2 / PAI-1Fibroblasts, multiple typesPhase 1/2 (combined with dasatinib)Weak alone; requires combination
D+Q CombinationCombination senolyticMultiple SCAPs pathwaysBroad spectrum (endothelial, fat, fibroblast)Multiple completed Phase 1/2Small human trials; placebo-controlled efficacy unclear
Navitoclax (ABT-263)BCL-2/BCL-xL inhibitorBCL-2 familyMultiple (broad)Oncology trials; not in aging trialsThrombocytopenia limits non-oncology use
FisetinFlavonoidMultiple (similar to quercetin)Similar to quercetinEarly human pilot trialsWeaker than D+Q; data limited
UBX0101MDM2 inhibitorMDM2/p53 pathwayp53-dependent senescent cellsPhase 2 failed (knee OA, 2020)Preclinical-clinical translation gap demonstrated

10. Connection to Telomere and Mitochondrial Research

  • Telomere shortening → senescence: Compounds that influence telomere length dynamics may theoretically influence the rate of replicative senescence initiation. See our Epitalon telomeres longevity research.
  • Mitochondrial dysfunction and senescence: Senescent cells typically have fragmented mitochondria with elevated ROS. Mitochondrial-derived peptides like MOTS-c are studied for mitochondrial stress responses. See our MOTS-c mitochondrial peptide research.
  • NAD+ and SASP regulation: The SASP is regulated partly via NAD+-dependent SIRT1 deacetylase activity. See our NAD+ injectable vs oral pharmacokinetics guide.
Dasatinib and quercetin mechanism — kinase inhibitor and flavonoid converging on senescent cell apoptosis

11. FAQ: Frequently Asked Questions

What is a senolytic compound?

A senolytic is a compound that selectively induces apoptosis in senescent cells — cells that have permanently stopped dividing but persist in tissues, secreting a harmful cocktail of inflammatory signals called the SASP. Senolytics exploit the upregulated pro-survival pathways that allow senescent cells to persist despite internal damage signals.

Is dasatinib approved as a senolytic?

No. Dasatinib is an approved cancer drug for CML and ALL. Its use in the senolytic research context is investigational. The D+Q protocol has been studied in early human trials but has not received regulatory approval as an aging intervention.

What were the key findings from the first human senolytic trial?

Justice et al. (2019, EBioMedicine, PMID 30616998) treated 14 patients with IPF with three doses of D+Q. They observed reductions in circulating senescent cell markers (p16Ink4a, p21CIP1), decreased SASP inflammatory markers (IL-6, TNF-α), and improvements in physical function tests. First human evidence that senolytic treatment reduces senescent cell burden in vivo.

Why do senolytics use intermittent rather than continuous dosing?

Senescent cells accumulate slowly and do not regenerate rapidly after clearance. Intermittent treatment — short courses every few weeks or months — provides sufficient senolysis while minimising cumulative drug exposure. This contrasts with the continuous dosing used for the same drugs in oncology.

What is the difference between senolytics and senomorphics?

Senolytics kill senescent cells. Senomorphics (rapamycin, certain JAK inhibitors) modify the SASP or senescent phenotype without eliminating the cells. Both reduce SASP-mediated damage, but senolytics address the cellular source while senomorphics address the secreted factors.

Are quercetin and fisetin available as research compounds?

Quercetin is available as a supplement in most jurisdictions; its use in the investigational senolytic context requires research ethics oversight. Fisetin is similarly supplement-available. When supplied by UNIK LAB as research chemicals, use requires appropriate institutional and ethics board approval.

Referenced Studies

  1. Baker DJ et al. “Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders.” Nature. 2011. PMID 22048312
  2. Zhu Y et al. “The Achilles' heel of senescent cells: from transcriptome to senolytic drugs.” Aging Cell. 2015. PMID 25754370
  3. Justice JN et al. “Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.” EBioMedicine. 2019. PMID 30616998
  4. Hickson LJ et al. “Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.” EBioMedicine. 2019. PMID 31542391
  5. Palmer AK et al. “Targeting senescent cells alleviates obesity-induced metabolic dysfunction.” Aging Cell. 2019. PMID 30907060
  6. Yousefzadeh MJ et al. “Fisetin is a senotherapeutic that extends health and lifespan.” EBioMedicine. 2018. PMID 30279143

Available from UNIK LAB

Research Compounds

Research-grade Research Compounds · HPLC verified ≥98% · COA included · 48h EU/UK dispatch

Browse All Compounds →

Related Research

Research Disclaimer: Dasatinib is an approved oncology drug; its use in the senolytic context is investigational and not approved for this indication. Quercetin, fisetin, and navitoclax in the senolytic research context are research compounds. All content is for informational and educational purposes only. UNIK LAB does not provide medical advice. Researchers must obtain appropriate ethical approval before conducting any human research involving these compounds.